[METRIC]
A-A-53075A
1 April 1993
SUPERSEDING
A-A-0053075 (DM)
5 July 1987
COMMERCIAL ITEM DESCRIPTION
DIFLUNISAL TABLETS, USP
The General Services Administration has authorized the use of this Commercial Item Description.
Salient Characteristics:
Shall be Diflunisal Tablets, USP.
Shall be in accordance with the requirements of the USP.
For Strength I, shall contain 250 mg of Diflunisal per tablet, within the applicable assay limits.
For Strength II, shall contain 500 mg of Diflunisal per tablet, within the applicable assay limits.
Each tablet shall be marked/embossed with a product identification code to identify the active ingredient(s), strength, and manufacturer. The materials used in marking/e*ossing the dosage forms shall be acceptable to the FDA. The actual code used for the product shall be left to the discretion of the supplier.
All ingredients entering into the manufacture of the tablets shall be of a pharmaceutical grade.
Workmanship. The tablets shall be free from defects which detract from their appearance or impair their serviceability.
DISTRIBUTION STATEMENT A. Approved for public release; distribution is unlimited.
For Parts Inquires submit RFQ to Parts Hangar, Inc.
© Copyright 2015 Integrated Publishing, Inc.
A Service Disabled Veteran Owned Small Business